Just Released |
||
Distributing a COVID-19 Vaccine Across the U.S. - A Look at Key
Issues Government
officials hope to identify one or more safe and effective COVID-19 vaccines
over the next few months as part of a multi-agency effort known as Operation
Warp Speed. If and when they succeed, their focus will shift to making sure
people across the country can access the vaccine. A
new issue brief lays out some of the key challenges
with such a massive vaccination effort, which could require hundreds of
millions of vaccine doses to be delivered across the country in a short
period of time. The brief describes the leading vaccine candidates for the
U.S. and what’s known about the federal government’s plans for distributing a
successful vaccine or vaccines across the country and the challenges,
including the potential need for billions of dollars in additional funding. It
also examines issues around supply, logistics and monitoring; the role of the
federal, state and local governments; insurance coverage and out-of-pocket
costs; racial and ethnic disparities; and building public confidence about
the vaccine’s safety and effectiveness. The
brief is part of KFF’s broader portfolio examining the health and
economic impacts of the COVID-19 pandemic, including original policy
analysis, polling and journalism. Filling
the need for trusted information on national health issues, KFF (Kaiser Family Foundation)
is a nonprofit organization based in San Francisco, California. |
||
|
||
To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Tuesday, October 20, 2020
Distributing a COVID-19 Vaccine Across the U.S. - A Look at Key Issues
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment